News stories about Cardlytics (NASDAQ:CDLX) have been trending somewhat positive on Tuesday, Accern reports. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cardlytics earned a coverage optimism score of 0.06 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.690837304096 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
NASDAQ:CDLX traded down $0.32 during trading hours on Tuesday, reaching $14.12. 130,174 shares of the stock were exchanged, compared to its average volume of 183,549. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of -0.27. Cardlytics has a twelve month low of $11.10 and a twelve month high of $20.99. The stock has a market capitalization of $284.34 and a price-to-earnings ratio of -1.76.
Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings data on Monday, March 19th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.35) by $0.25. The company had revenue of $39.27 million during the quarter, compared to analyst estimates of $38.48 million. sell-side analysts expect that Cardlytics will post -1.93 EPS for the current fiscal year.
CDLX has been the topic of a number of research reports. SunTrust Banks initiated coverage on Cardlytics in a research note on Tuesday, March 6th. They set a “buy” rating and a $25.00 price target on the stock. JPMorgan Chase initiated coverage on Cardlytics in a research note on Tuesday, March 6th. They set an “overweight” rating and a $23.00 price target on the stock. KeyCorp initiated coverage on Cardlytics in a research note on Tuesday, March 6th. They set an “overweight” rating and a $23.00 price target on the stock. Wells Fargo initiated coverage on Cardlytics in a research note on Tuesday, March 6th. They set an “outperform” rating and a $22.00 price target on the stock. Finally, Bank of America initiated coverage on Cardlytics in a research note on Tuesday, March 6th. They set a “neutral” rating and a $19.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $22.40.
In related news, CEO Scott D. Grimes acquired 2,600 shares of Cardlytics stock in a transaction dated Tuesday, February 13th. The shares were acquired at an average cost of $13.00 per share, for a total transaction of $33,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
TRADEMARK VIOLATION NOTICE: “Cardlytics (CDLX) Receives Daily Media Sentiment Rating of 0.06” was originally published by Zolmax and is owned by of Zolmax. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://zolmax.com/investing/cardlytics-cdlx-receives-daily-media-sentiment-rating-of-0-06/2112571.html.
Cardlytics Company Profile
Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.